These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37772709)

  • 21. Everolimus: a new hope for patients with breast cancer.
    Sendur MA; Zengin N; Aksoy S; Altundag K
    Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Dopamine Receptors in the Anticancer Activity of ONC201.
    Kline CLB; Ralff MD; Lulla AR; Wagner JM; Abbosh PH; Dicker DT; Allen JE; El-Deiry WS
    Neoplasia; 2018 Jan; 20(1):80-91. PubMed ID: 29216597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
    Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
    Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.
    Yunokawa M; Koizumi F; Kitamura Y; Katanasaka Y; Okamoto N; Kodaira M; Yonemori K; Shimizu C; Ando M; Masutomi K; Yoshida T; Fujiwara Y; Tamura K
    Cancer Sci; 2012 Sep; 103(9):1665-71. PubMed ID: 22703543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
    Martin LA; Pancholi S; Farmer I; Guest S; Ribas R; Weigel MT; Thornhill AM; Ghazoui Z; A'Hern R; Evans DB; Lane HA; Johnston SR; Dowsett M
    Breast Cancer Res; 2012 Oct; 14(5):R132. PubMed ID: 23075476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experimental and computational assessment of the synergistic pharmacodynamic drug-drug interactions of a triple combination therapy in refractory HER2-positive breast cancer cells.
    Vaidya TR; Ait-Oudhia S
    J Pharmacokinet Pharmacodyn; 2022 Apr; 49(2):227-241. PubMed ID: 34773540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).
    Liguori NR; Sanchez Sevilla Uruchurtu A; Zhang L; Abbas AE; Lee YS; Zhou L; Azzoli CG; El-Deiry WS
    Am J Cancer Res; 2022; 12(2):729-743. PubMed ID: 35261798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic and inflammatory reprogramming of macrophages by ONC201 translates in a pro-inflammatory environment even in presence of glioblastoma cells.
    Geiß C; Witzler C; Poschet G; Ruf W; Régnier-Vigouroux A
    Eur J Immunol; 2021 May; 51(5):1246-1261. PubMed ID: 33442873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
    Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Everolimus.
    Hasskarl J
    Recent Results Cancer Res; 2018; 211():101-123. PubMed ID: 30069763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
    Fukui F; Hayashi SI; Yamaguchi Y
    J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial.
    Royce M; Bachelot T; Villanueva C; Özgüroglu M; Azevedo SJ; Cruz FM; Debled M; Hegg R; Toyama T; Falkson C; Jeong J; Srimuninnimit V; Gradishar WJ; Arce C; Ridolfi A; Lin C; Cardoso F
    JAMA Oncol; 2018 Jul; 4(7):977-984. PubMed ID: 29566104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
    Allen JE; Krigsfeld G; Patel L; Mayes PA; Dicker DT; Wu GS; El-Deiry WS
    Mol Cancer; 2015 May; 14():99. PubMed ID: 25927855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.
    Bihani T; Ezell SA; Ladd B; Grosskurth SE; Mazzola AM; Pietras M; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2015 Feb; 6(4):2407-20. PubMed ID: 25537515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microarray analysis reveals ONC201 mediated differential mechanisms of CHOP gene regulation in metastatic and nonmetastatic colorectal cancer cells.
    Al Madhoun A; Haddad D; Al Tarrah M; Jacob S; Al-Ali W; Nizam R; Miranda L; Al-Rashed F; Sindhu S; Ahmad R; Bitar MS; Al-Mulla F
    Sci Rep; 2021 Jun; 11(1):11893. PubMed ID: 34088951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.
    Yeung Y; Lau DK; Chionh F; Tran H; Tse JWT; Weickhardt AJ; Nikfarjam M; Scott AM; Tebbutt NC; Mariadason JM
    Mol Oncol; 2017 Sep; 11(9):1130-1142. PubMed ID: 28544747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options.
    Rugo HS; Vidula N; Ma C
    Am Soc Clin Oncol Educ Book; 2016; 35():e40-54. PubMed ID: 27249746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitory effects of everolimus in combination with paclitaxel on adriamycin-resistant breast cancer cell line MDA-MB-231.
    Xu T; Liu P; Li Q; Shi C; Wang X
    Taiwan J Obstet Gynecol; 2020 Nov; 59(6):828-834. PubMed ID: 33218396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. mTOR inhibitors in advanced breast cancer: ready for prime time?
    Martin LA; André F; Campone M; Bachelot T; Jerusalem G
    Cancer Treat Rev; 2013 Nov; 39(7):742-52. PubMed ID: 23557794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells.
    Simone V; Ciavarella S; Brunetti O; Savonarola A; Cives M; Tucci M; Opinto G; Maiorano E; Silvestris F
    BMC Cancer; 2015 Oct; 15():692. PubMed ID: 26468083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.